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With white blood cell count emerging as an important risk factor for chronic inflammatory diseases, genetic
associations of differential leukocyte types, specifically monocyte count, are providing novel candidate
genes and pathways to further investigate. Circulating monocytes play a critical role in vascular diseases
such as in the formation of atherosclerotic plaque. We performed a joint and ancestry-stratified genome-
wide association analyses to identify variants specifically associated with monocyte count in 11 014 subjects
in the electronic Medical Records and Genomics Network. In the joint and European ancestry samples, we
identified novel associations in the chromosome 16 interferon regulatory factor 8 (IRF8) gene (P-value 5
2.78310(216), b 5 20.22). Other monocyte associations include novel missense variants in the chemo-
kine-binding protein 2 (CCBP2) gene (P-value 5 1.88310(27), b 5 0.30) and a region of replication found
in ribophorin I (RPN1) (P-value 5 2.63310(216), b 5 20.23) on chromosome 3. The CCBP2 and RPN1
region is located near GATA binding protein2 gene that has been previously shown to be associated with cor-
onary heart disease. On chromosome 9, we found a novel association in the prostaglandin reductase 1 gene
(P-value 5 2.29310(27), b 5 0.16), which is downstream from lysophosphatidic acid receptor 1. This region
has previously been shown to be associated with monocyte count. We also replicated monocyte associations
of genome-wide significance (P-value 5 5.68310(217), b 5 20.23) at the integrin, alpha 4 gene on chromo-
some 2. The novel IRF8 results and further replications provide supporting evidence of genetic regions asso-
ciated with monocyte count.
INTRODUCTION
The white blood cells (WBCs) are key regulators of the
immune system. The differential leukocyte types are reported
as a proportion of the total WBC count and have different im-
munological functions. In order of predominance, these types
include neutrophils, lymphocytes, monocytes, eosinophils and
basophils. Whereas environmental influences (infection, aller-
gen exposure, medications, etc.) are likely responsible for the
majority of intra-individual variability in acute differential
counts, inter-individual differences in chronic ‘resting state’
differential counts are known to be heritable traits (1,2).
Each cell type matures from hematopoietic stem cells, and
the control of the homeostasis of these cell populations con-
tinues to be a focus of intense research (3).
Monocytes and some dendritic cells arise from the differen-
tiation of a common precursor, and monocytes themselves can
differentiate into dendritic cells under proper conditions. Most
monocytes are destined to mature into macrophages. These
cells have broad roles in inflammation, autoimmunity and pro-
tection from infection and cancer. Understanding the genetic
mechanisms influencing monocyte homeostasis could
provide insight into the etiology of a variety of disease
states. Whereas total WBC has been analyzed for genetic asso-
ciations several times (4–6), monocyte count has generally
been studied less frequently.
Several loci have been reported to be associated with the
monocytes. Integrin, alpha 4 (ITGA4), has been associated in
multiple cohorts (1,2,7). ITGA4 encodes a receptor for fibronec-
tin in leukocyte cell lines. It may also participate in T-cell
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interactions with target cells (8). The association of monocytes
with variants at the intergenic region at 9q31, lysophosphatidic
acid receptor 1 (LPAR1), has also been reported by multiple
studies (1,7). LPAR1 is a lysophosphatidic acid (LPA) receptor
and mediates diverse biologic functions including proliferation,
platelet aggregation, smooth muscle contraction, inhibition of
neuroblastoma cell differentiation, chemotaxis and tumor cell
invasion (8). Monocyte count associations with the MHC
region and near syntaxin-binding protein 6 in a Japanese
cohort (2) did not replicate in the large meta-analysis across
populations of diverse ancestral background, but did for the
8q24 intergenic region (1). Inconsistent monocyte genome-
wide association studies (GWAS) results suggest that clarifica-
tion is needed to identify loci with consistent impact or race-
specific impact. There is increasing evidence that large datasets
are required to identify biologically relevant common variants.
In this study, we performed a pooled and genetically determined
ancestry (GDA)-stratified analysis of monocyte count using
11 014 subjects in the electronic Medical Records and Genom-
ics (eMERGE) Network (4). The Network, consisting of five US
cohorts, was linked to electronic medical records (EMRs) for
collecting phenotypes. Having access to multiple WBC differ-
entials measured over many years for the duration of the EMR
allowed for genomic association with chronic ‘resting state’
of the monocyte count. We were able to assess monocyte
count distribution for each subject and allow for the removal
of outliers that could be due to environmental conditions like
an infection. This is a distinct advantage for such phenotypes
with large variability due to environmental conditions that
could introduce bias or reduce power. Having access to multiple
observations over multiple years also presented challenges and
opportunities to assess different association methods utilizing
repeated measures from observational data.
RESULTS
Descriptive statistics by eMERGE study site
Table 1 contains descriptive statistics of total monocyte count
along with the covariates stratified by eMERGE study site and
combined. Northwestern University (23.1%) and Vanderbilt
University (32.5%) had the highest proportions of participants
who self-identified or were observed reported as having
African ancestry (AA) that was generally supported by the
genetically determined recent ancestry. There was a significant
difference (P , 0.0001) in monocyte count by site, with
Marshfield Clinic and Mayo Clinic having the highest
median values of 8.4 and 8.6%, respectively. Supplementary
Material, Figure S3 illustrates the multivariate effects of pre-
dictors on monocyte count for site and interquarile ranges
for median BMI, median age and eigenvector 1 and eigen-
vector 2 from the ancestry principal component analysis
(PCA). All covariates in the multivariate were significant
(P-value , 0.0001) except for eigenvector 1 that was moder-
ately significant (P-value ¼ 0.03).
Monocyte count association
Novel variant associations
Table 2 outlines variants (both novel and replicated) that
reached or approached genome-wide significance for the
joint (l ¼ 1.032), European ancestry (EA) stratified (l ¼
1.024) or AA stratified (l ¼ 1.004) analyses of monocyte
count. The Manhattan and QQ plots are illustrated in
Figure 1 and Supplementary Material, Figure S1, respectively.
To ensure that ancestry-specific admixture was not yielding
false positives, we additionally included eigenvectors 1 and
2 to each ancestry-stratified multivariate model that resulted
in nominal differences in genomic inflation (l ¼ 1.021 and
l ¼ 1.006). The Manhattan and QQ plots are illustrated in
Supplementary Material, Figures S3 and S4, respectively.
We identified three separate novel monocyte genetic variant
associations, one on chromosome 3 in CCBP2, one on
chromosome 16 in the interferon regulatory factor 8 gene
(IRF8) and one in PTGR1 (Table 2). Figure 1 illustrates the
Manhattan plots for these analyses. QQ plots are shown in
Supplementary Material, Figure S1. For the most part, the
novel associations identified in the joint analyses were
driven by the larger EA group and supported by the results
found in the EA-enriched sites (Group Health, Marshfield
Table 1. Summary statistics of demographic data and phenotypes by eMERGE participating site and combined. The number of records per site is listed under site












(n ¼ 11 014)
Sex (M) 41% (754) 41% (1492) 62% (1646) 43% (473) 36% (641) 46% (5006)
Median BMI 27.0 + 5.1 29.5 + 5.9 28.7 + 5.2 30.8 + 8.3 29.9 + 7.6 29.1 + 6.3
Median age 74.2 + 8.0 61.2 + 11.9 64.0 + 9.1 52.4 + 13.6 50.0 + 16.5 61.4 + 14.1
Self-reported race
American Indian or Alaska Native 0.1% (2) 0.6% (22) 0.2% (5) 0.0% (0) 0.0% (0) 0.3% (29)
Asian 2.7% (50) 0.3% (10) 0.1% (2) 0.0% (0) 0.1% (3) 0.6% (62)
Black or African American 3.2% (59) 0.1% (3) 0.3% (8) 26.8% (297) 34.6% (622) 9.0% (989)
Other 1.2% (22) 0.4% (13) 0.4% (10) 0.0% (0) 0.1% (2) 0.4% (47)
White 92.6% (1705) 98.7% (3566) 94.7% (2513) 73.2% (812) 57.2% (1028) 87.4% (9624)
Unknown 0.2% (3) 0.0% (0) 4.3% (115) 0.0% (0) 8.1% (145) 2.4% (263)
GDA of African continent 2.6% (47) 0.1% (2) 0.2% (5) 23.1% (256) 32.5% (584) 8.1% (894)
GDA of European continent 93.1% (1714) 99.2% (3586) 98.9% (2625) 70.7% (784) 63.4% (1140) 89.4% (9849)
Median monocytes (%) 7.6 + 2.4 8.4 + 1.9 8.6 + 1.9 7.9 + 2.2 7.1 + 2.4 8.0 + 2.2
x + I represents X+1 SD for continuous variables.
Numbers after percentages are frequencies.
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Clinic and Mayo Clinic; see site specific results, Table 3). In
some cases, the AA results were consistent with the European
results, but not significant at a genome-wide level.
For the CCBP2 joint analysis, there are multiple variants
found within the peak on chromosome 3; we report two
based on significance and function (Table 2). Both rs2228467
and rs2228468 are missense variants, V[VAL]  A[ALA]
and Y[TYR]  S[SER], respectively. The rs2228467 variant
is the most significant [P-value ¼ 1.57×10(207)] with effect
size of b ¼ 0.30 and has a minor allele frequency (MAF) of
0.06 in our joint sample. The minor allele for rs2228467 was
associated with a lower monocyte count. Similar effects were
seen in the EA group (P-value ¼ 2.39×10(208); b ¼ 0.32),
but not the AA group. The other CCBP2 missense variant
(rs2228468; MAF¼ 0.36) is not in LD with rs2228467 (r2 ¼
0.04), but this is most likely due to the large difference in
MAF between the variants. The joint and EA analyses produced
similarly significant results for rs2228468 [P-values¼
5.15×10(207), 6.93×10(207)] and effect sizes (b ¼ 20.14,
b ¼ 20.15) for this variant. Unlike rs2228467, the minor
allele for rs2228468 is not associated with a lower monocyte
count. Both missense variants in CCBP2 were not significant
in our smaller AA group [P-value ≥ 3.87×10(201)], and the
direction of effect was mixed with respect to the joint and
EA analyses.
There are also multiple variants in LD found within the peak
on chromosome 16 at IRF8, so we report the most significantly
associated variant. Again, the joint and EA analyses results for
rs424971 (intronic) have similar significance [P-values ¼
3.16×10(216), 6.32×10(218)] and effect size (b ¼ 20.23,
b ¼ 20.25). The minor allele for rs424971 (EA MAF¼
0.44) is associated with a lower monocyte count. None of the
variants in the region were significant in our AA analyses.
Our PTGR1 results suggest a novel monocyte-associated
gene of 680 kb from previously reported association to var-
iants in the LPAR1 gene on chromosome 9 (1,7). The EA
group again drove the association in our sample. The joint ana-
lysis for rs2273788 (intronic) produced marginal genome-wide
significance (P-value ¼ 4.50×10(207), b ¼ 0.16), as did the
EA analysis (P-value ¼ 1.59×10(207), b ¼ 0.17). In both
groups, the minor allele for rs424971 was associated with a
higher monocyte count. We also included the previously
reported LPAR1 variants in the multivariate model to
perform conditional analyses (1,7). Both rs7023923 and
rs10980800 were separately included in the model, and the
significance of rs2273788 was assessed. In general, neither
variant significantly changed our rs2273788 association
results (P-value ¼ 8.23×10(207) and 7.92×10(207), re-
spectively).
Replicated variant associations
We replicated previously reported findings in two regions -
ITGA4 on chromosome 2 and RPN1 on chromosome 3 (1,2).
The most significant variant in the joint analysis is an intronic
single nucleotide polymorphism (SNP) (rs2124440, P-value ¼
4.63×10(217), b ¼ 20.22). Subjects with the rs2124440
minor allele on average have lower monocyte count. The EA
analysis results reached genome-wide significance (P-value ¼
1.35×10(214), b ¼ 20.22), and the smaller AA results were
highly consistent (P-value ¼ 5.70×10(203), b ¼ 20.31). In
both ancestry groups, the minor allele for rs2124440 predicted
a lower monocyte count. We also replicated an association of
RPN1 with a variant (rs2712381) located near the 3′ end.
This variant was significant in all the groups, with the joint
and EA analysis yielding P-values¼ 1.94×10(216),
4.52×10(214) with b ¼ 20.23, 20.22, respectively. The
AA analysis had the same direction of effect (P-value ¼
1.50×10(203), b ¼ 20.36). In all ancestry groups, the
rs2712381 minor allele predicted a lower monocyte count.
Replication in additional cohorts (CHARGE Hematology
Working Group)
We compared our novel and replicated results of variants
reaching genome-wide significance with the results from the
same variants in a meta-analysis of 19 509 subjects in seven
CHARGE cohorts (1). The cohorts include the following
studies: (i) The Rotterdam Study (RS), (ii) Framingham
Heart Study (FHS), (iii) the NHLBI’s Atherosclerosis Risk
in Communities (ARIC) Study; (iv) the Age, Gene/Environ-
ment Susceptibility—Reykjavik Study (AGES) Study, (iv)
Health Aging and Body Composition Study (Health ABC),
(vi) the Baltimore Longitudinal Study of Aging (BLSA) and
(vii) the Invecchiare in Chianti Study (InChianti). The
meta-analyses were performed using the inverse-variance
weighted fixed effects model to combine b coefficients and
standard errors (SE) (1). The meta-analysis P-values, alleles,
bs and SEs are listed in Table 4. We also included adjusted
effect (based on strand), if aligned to the eMERGE MAF.
For all variants, the directions of effect are the same as we
report. The ITGA4 variant (rs2124440) was significant at a
genome-wide level in the meta-analysis (P-value ¼
6.93×10(214)). The variants in RPN1 (rs2712381), PTGR1
Table 2. Summary of effects of loci that reached monocyte count genome-wide significance for the joint (n¼11 014), EA (n ¼ 9849) and AA (n¼887) analyses.
Actual numbers for the analyses may vary due to missing phenotype and/or covariate data
CHR SNP A BP (GRCh37/hg19) Joint MAF P-value (b) EA P-value (b) AA P-value (b) Gene Function
(a) Novel variant associations
3 rs2228467 G 42906116 0.06 1.57×10(207) (0.30) 2.39×10(208) (0.32) 3.90×10(201) (20.39) CCBP2 Missense
3 rs2228468 C 42907112 0.36 5.15×10(207) (20.14) 6.93×10(207) (20.15) 3.87×10(201) (20.11) CCBP2 Missense
9 rs2273788 A 114348617 0.26 4.50×10(207) (0.16) 1.59×10(207) (0.17) 5.62×10(202) (20.02) PTGR1 Intronic
16 rs424971 G 85946450 0.47 3.16×10(216) (20.22) 6.32×10(218) (20.25) 5.93×10(201) (20.07) IRF8 Intronic
(b) Replicated variant associations
2 rs2124440 G 182328214 0.45 4.63×10(217) (20.22) 1.35×10(214) (20.22) 5.70×10(203) (20.31) ITGA4 Intronic
3 rs2712381 A 128338600 0.40 1.94×10(216) (20.23) 4.52×10(214) (20.22) 1.50×10(203) (20.36) RPN1 Near 3′
BP, base pair; CHR, chromosome; SNP, single nucleotide polymorphism.
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(rs2273788) and IRF8 (rs424971) were significant at levels suffi-
cient for replication, but not at a genome-wide level (P-values ¼
1.50×10(202), 3.97×10(203) and 2.32×10(205), respect-
ively). Variants for CCBP2 (rs2228467 and rs2228468) did
not reach a significance of P-value¼ 5.00×10(202).
DISCUSSION
This genome-wide assessment of circulating monocyte count
prediction in the eMERGE Network identified novel variants
in CCBP2, IRF8 and PTGR1 and validated previous genes
reported to be associated with monocyte count—ITGA4 and
RPN1 (2,5). The fact we were able to replicate previous asso-
ciations increases confidence in the phenotypes and, thus, in
the currently reported novel associations of CCBP2, IRF8
and PTGR1. PTGR1 lies in a chromosomal region that had
showed prior association LPAR1; these results may provide
an additional clue to that region’s association with monocyte
count. The large number of subjects with repeated measures
over a number of years through the EMR provided an assess-
ment of an individual’s underlying resting state. This was a
distinct advantage over other studies, as we had both repeated
measures and the ability to remove environmental variation
due to factors such as medications or infections. These advan-
tages may have allowed the discovery of the novel findings we
report.
Chemokines, such as that coded for by CCBP2, are small
molecules that play a role in cell chemotaxis, including the re-
cruitment of effector immune cells to the inflammation site
(8). The role of chemokines in the recruitment of macrophages
and dendritic cells could obviously affect monocyte develop-
ment. The direction of effect and the interplay of the two mis-
sense variants (rs2228467 and rs228468) will be further
explored in future studies.
Figure 1. From top to bottom, Manhattan plots of P-values from monocyte count association analyses in the joint, EA and AA groups, respectively.
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IRF8 is another excellent candidate given its role with in-
flammatory signaling. Although common variation in IRF8
has not previously been found to be associated with monocyte
count, existing biologic evidence supports this as the causative
locus underlying the GWAS signal identified here. IRF8 codes
for a transcription factor of the interferon (IFN) regulatory
factor (IRF) family (8) that is known to be important in mono-
cyte differentiation (9–11). Coding mutations in IRF8 were
recently identified as underlying both an autosomal dominant
and an autosomal recessive deficiency of dendritic cells in
humans (12), clearly demonstrating the importance of IRF8
in dendritic cell levels. IFNs are also signaling molecules
that are released by host cells in the presence of pathogens.
This signaling triggers the protective defenses of the
immune system to eradicate infected cells that include macro-
phages and dendritic cells. In addition to regulating the IFN
system, the IRF family participates in directing the develop-
ment of innate and adaptive immunity (13).
We were also able to replicate and/or provide further clari-
fication of monocyte count associations reported by others.
Our ITGA4 and RPN1 results provide further evidence that
these genes or regions do influence monocyte count.
Whereas the LPAR1 gene has previously been reported to be
associated with monocyte count, we have reported the associ-
ation of a nearby gene PTGR1. This gene encodes an enzyme
that is involved in the inactivation of the chemotactic factor,
leukotriene B4 (8). All variants we presented were replicated
in the seven-cohort meta-analysis, except those in CCBP2.
Because the novel CCBP2 variants (rs2228467 and
rs2228468) did not replicate, despite being an excellent candi-
date gene, further validation efforts are warranted. Our novel
and replicated association results demonstrate genetic variants
influencing monocyte count that are not identified for total
WBC and may be relevant to WBC differentiation.
MATERIALS AND METHODS
Selection and description of participants
The selection and description of participants are documented
in a previous study (4). The eMERGE Network is a consor-
tium of US cohorts linked to EMR data for conducting
large-scale, high-throughput genetic research (14). The partici-
pating sites included the following: (i) Group Health Coopera-
tive, University of Washington and Fred Hutchinson Cancer
Research Center partnership, Seattle, WA, USA, (ii) Marsh-
field Clinic, Marshfield, WI, USA, (iii) Mayo Clinic, Roches-
ter, MN, USA, (iv) Northwestern University, Chicago, IL,
USA and (v) Vanderbilt University, Nashville, TN, USA
that also served as the Coordinating Center (15). The Center
for Inherited Disease Research (CIDR) at Johns Hopkins Uni-
versity and The Broad Institute of MIT and Harvard served as
the genotyping centers for the Network.
Like the previously published total WBC data (4), the dif-
ferential extraction algorithm for EMRs was developed and
validated by Group Health and the University of Washington.
As outlined in detail in that paper, we attempted to exclude
any visit and/or subject whose values were possibly reflective
of something other than resting state differential counts.
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at any time. Visit-level exclusions are grouped into three cat-
egories: (i) any medications (including chemotherapy) that
could affect the immune system, (ii) any indication of an in-
fection and (iii) a diagnosis that we deemed a confounder
with respect to levels of monocyte count (i.e. a diagnosis of
Alzheimer’s disease).
Defining GDA
As presented previously (4), to define the genetically deter-
mined EA sample, we identified all subjects with values less
than three (+3) and greater than negative one (21) SD
from the means of eigenvectors 1 and 2 of self-identified
EA, respectively. For genetically determined AA, we identi-
fied all subjects with values less than two (+2) and greater
than negative one (21) SD from the mean of eigenvector 1
and less than and greater than one SD (+1) for eigenvector
2 of self-identified AA subjects, respectively. Respective
numbers of self-identified and GDA are listed in Table 1. To
control for ancestry-specific admixture, PCA was performed
within each respective ancestry group (Supplementary Mater-




As reported previously (4), most subjects were genotyped on
the Illumina Human660W-Quadv1_A (660 W) genotyping
platform. A subset of subjects who were self-reported (North-
western) or observer reported (Vanderbilt University) to have
AA was genotyped on the Illumina Human1M-Duo (1 M)
genotyping platform. Genotyping calls for both platforms
were made at CIDR and Broad using BeadStudio version
3.3.7 and Gentrain version 1.0. Both samples and SNPs
were assessed for quality and subsequently filtered from the
production data, if thresholds were not met. Cryptic related-
ness was assessed for all sites, and pairs at half-sibling level
(kinship coefficient u ¼ k1/4 + k2/2 ¼ 1/8) or higher were ran-
domly broken (by dropping one) before assessing whole-
genome association. Subjects identified for filtering at each
particular site through the quality control/quality assurance
process were subsequently filtered for the entire merged
dataset.
Statistics
Analyses of monocyte count as a quantitative phenotype (or-
dinary least squares) with the given covariates and genotypes
were performed in PLINK (16). For subjects with repeated
measures, median values for monocytes, BMI and age were
utilized in the linear model. For consistency with the WBC
count analyses (4), covariates included sex, median BMI,
median age, eigenvectors 1 and 2. For the joint analysis,
study site was included as a covariate. For the ancestry-
stratified analyses, eigenvectors 1 and 2 were dropped from
the model. Subsequently, eigenvectors 1 and 2 from each
ancestry-specific PCA were added to the model and reana-
lyzed to ensure that ancestry-specific admixture was not yield-
ing false positives. SNP genotypes were coded as 0, 1 and 2
copies of the minor allele (additive genotypic model). In
general, we deemed genome-wide significance at P-value ,
5.0×10(28) that approximates a Bonferroni correction for ap-
proximately 1 000 000 independent hypothesis tests (17).
WEB RESOURCES
eMERGE website: http://www.gwas.net
R package Hmisc: http://cran.r-project.org/web/packages/
Hmisc/index.html
R package rms: http://cran.r-project.org/web/packages/rms/
index.html
R package SNPRelate: http://cran.r-project.org/web/packa
ges/SNPRelate/index.html
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